Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents

• Published in: Hepatology communications Vol. 3; no. 8; pp. 1085 - 1097
• Main Authors: Hernandez, Eloy D., Zheng, Lianxing, Kim, Young, Fang, Bin, Liu, Bo, Valdez, Reginald A., Dietrich, William F., Rucker, Paul V., Chianelli, Donatella, Schmeits, James, Bao, Dingjiu, Zoll, Jocelyn, Dubois, Claire, Federe, Glenn C., Chen, Lihao, Joseph, Sean B., Klickstein, Lloyd B., Walker, John, Molteni, Valentina, McNamara, Peter, Meeusen, Shelly, Tully, David C., Badman, Michael K., Xu, Jie, Laffitte, Bryan
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.08.2019; John Wiley and Sons Inc; Wolters Kluwer Health/LWW
• Subjects: Bile; Cytochrome; Experiments; Fibroblasts; Gene expression; Growth factors; Inflammation; Laboratory animals; Ligands; Lipids; Liver diseases; Metabolism; Metabolites; Mortality; Original; Oxidative stress; Polyethylene glycol; Polymerase chain reaction; Transplants & implants; Variance analysis; Japan

Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we r...